IMVT analyst estimates
Immunovant (IMVT) analyst ratings, the average price target and its range, and every firm's latest call.
IMVT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| May 21, 2026 | H.C. Wainwright | Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright | $40.00 |
| Jan 6, 2026 | Wolfe Research | Immunovant upgraded to Outperform at Wolfe on improving Graves' perception | $50.00 |
| Dec 18, 2025 | Guggenheim | Immunovant price target lowered to $41 from $44 at Guggenheim | $41.00 |
| Oct 14, 2025 | Truist Financial | Immunovant initiated with a Hold at Truist | $16.00 |
| Sep 10, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT) | $51.00 |
| Jun 3, 2024 | Oppenheimer | Immunovant price target lowered to $46 from $50 at Oppenheimer | $46.00 |
| May 30, 2024 | Piper Sandler | Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT) | $57.00 |
| May 30, 2024 | Guggenheim | Immunovant (IMVT) PT Lowered to $48 at Guggenheim | $48.00 |
| Mar 13, 2024 | Goldman Sachs | Goldman Sachs Starts Immunovant (IMVT) at Buy | $50.00 |
| Sep 26, 2022 | UBS | Immunovant downgraded to Neutral from Buy at UBS | $5.00 |
- 8 firms rate IMVT: 6 buy, 2 hold, 0 sell.
- The average price target is $40.00 from 1 analysts, from $40.00 to $40.00.
Updated 2026-11-02 23:10 UTC